Used in the treatment of severe asthma and chronic obstructive pulmonary disease (COPD), this antibody targets the IL-33 pathway to reduce airway inflammation. By blocking the IL-33 receptor (ST2), it helps prevent the activation of immune cells involved in type 2 inflammation, such as eosinophils and group 2 innate lymphoid cells. This leads to fewer exacerbations and improved lung function in patients with eosinophilic or allergic inflammatory phenotypes. It is also being studied in other inflammatory conditions like atopic dermatitis and nasal polyposis. Administered via subcutaneous injection, it offers a targeted biologic therapy option for patients unresponsive to standard treatments.